CONMED Corporation Reports Third Quarter 2026 Financial Results; Updates Full Year 2026 Guidance
CONMED reported Q3 2026 sales of $335.6 million, down 0.7% year-over-year as reported, but up 6.7% on an organic constant-currency basis excluding its exited GI product lines. GAAP diluted EPS was $0.66 (up 613.7%) while adjusted diluted EPS was $1.04, down 3.2%; the CEO said adjusted EPS exceeded management's expectations on balanced Orthopedic and General Surgery contributions.
Key figures
- Eps
- 0.66
- Revenue
- 335600000
- Guidance
- FY26 net sales $1,360M-$1,366M (prior $1,358M-$1,373M); adjusted diluted EPS $4.54-$4.61 (prior $4.48-$4.60); organic constant currency sales growth 5.0%-5.5%
- Revenue Yoy
- -0.7%
- Gross margin
- 56.4%
- Adjusted ebitda
- 67878000
- Adjusted eps yoy
- -3.2%
- Operating margin
- 11.1%
- Domestic sales yoy
- -11.0%
- Adjusted diluted eps
- 1.04
- Adjusted ebitda margin
- 20.2%
- International sales yoy
- 13.1%
- Organic constant currency growth
- 6.7%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.